SOPH (SOPHiA GENETICS SA Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by SOPH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | KATHY L HIBBS | Director | Sell | — | — |
| 2026-08-31 | Zhenyu Xu | Chief Scientific Officer | Sell | — | — |
| 2026-08-26 | Abhimanyu Verma | Chief Technology Officer | Sell | — | — |
| 2026-08-26 | Philippe Menu | Chief Medical Officer | Sell | — | — |
| 2026-08-26 | KATHY L HIBBS | Director | Sell | — | — |
| 2026-08-21 | Manuela Valente | Chief People Officer | MIXED | — | — |
| 2026-08-21 | Zhenyu Xu | Chief Scientific Officer | Sell | — | — |
| 2026-08-14 | Philippe Menu | Chief Medical Officer | Sell | — | — |
| 2026-08-14 | Zhenyu Xu | Chief Scientific Officer | Sell | — | — |
| 2026-08-10 | Abhimanyu Verma | Chief Technology Officer | Sell | — | — |
| 2026-08-10 | Jurgi Camblong | Executive Chairman | Sell | — | — |
| 2026-08-07 | Zhenyu Xu | Chief Scientific Officer | MIXED | — | — |
| 2026-08-07 | Zhenyu Xu | Chief Scientific Officer | MIXED | — | — |
| 2026-08-05 | Jurgi Camblong | Executive Chairman | Sell | — | — |
| 2026-08-05 | Abhimanyu Verma | Chief Technology Officer | Sell | — | — |
| 2026-08-05 | Zhenyu Xu | Chief Scientific Officer | Sell | — | — |
| 2026-07-28 | Philippe Menu | Chief Medical Officer | Sell | — | — |
| 2026-07-22 | Jurgi Camblong | Executive Chairman | MIXED | — | — |
| 2026-07-14 | Jurgi Camblong | Executive Chairman | Sell | — | — |
| 2026-07-14 | Zhenyu Xu | Chief Scientific Officer | Sell | — | — |
| 2026-07-14 | Philippe Menu | Chief Medical Officer | Sell | — | — |
| 2026-07-08 | Jurgi Camblong | Executive Chairman | Sell | — | — |
| 2026-07-07 | Manuela Valente | Chief People Officer | Sell | — | — |
| 2026-07-07 | Jurgi Camblong | Executive Chairman | Sell | — | — |
| 2026-07-07 | Ross Muken | Chief Executive Officer | Sell | — | — |
| 2026-07-07 | Abhimanyu Verma | Chief Technology Officer | Sell | — | — |
| 2026-07-07 | Zhenyu Xu | Chief Scientific Officer | Sell | — | — |
| 2026-07-07 | Philippe Menu | Chief Medical Officer | Sell | — | — |
| 2026-07-07 | Kevin Puylaert | Chief Sales Officer | Sell | — | — |
| 2026-07-07 | GEORGE CARDOZA | Chief Financial Officer | Sell | — | — |
| 2026-07-01 | Jurgi Camblong | Executive Chairman | MIXED | — | — |
| 2026-06-29 | Jurgi Camblong | Chief Executive Officer | MIXED | — | — |
| 2026-06-26 | Abhimanyu Verma | Chief Technology Officer | Sell | — | — |
| 2026-06-26 | Philippe Menu | Chief Medical Officer | Sell | — | — |
| 2026-06-23 | Ross Muken | President | Sell | — | — |
| 2026-06-23 | GEORGE CARDOZA | Chief Financial Officer | Sell | — | — |
| 2026-06-22 | KATHY L HIBBS | Director | A | — | — |
| 2026-06-22 | Jean-Michel Cossery | Director | A | — | — |
| 2026-06-22 | Vincent Ossipow | Director | A | — | — |
| 2026-06-22 | DIDIER HIRSCH | Director | A | — | — |
| 2026-06-22 | Troy Cox | Director | A | — | — |
| 2026-06-17 | Zhenyu Xu | Chief Scientific Officer | Sell | — | — |
| 2026-06-15 | Philippe Menu | Chief Medical Officer | Sell | — | — |
| 2026-06-11 | Jurgi Camblong | Chief Executive Officer | Sell | — | — |
| 2026-06-05 | GEORGE CARDOZA | Chief Financial Officer | Buy | — | — |
| 2026-06-01 | Philippe Menu | Chief Medical Officer | Sell | — | — |
| 2026-05-20 | Kevin Puylaert | Chief Sales Officer | Sell | — | — |
| 2026-05-20 | Ross Muken | President | Sell | — | — |
| 2026-05-20 | Philippe Menu | Chief Medical Officer | Sell | — | — |
| 2026-05-20 | Zhenyu Xu | Chief Scientific Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Executive Chairman | 3,444,322 | — |
| — | Chief Executive Officer | 670,651 | — |
| — | Chief Scientific Officer | 556,887 | — |
| — | Director | 522,860 | — |
| — | Chief Legal Officer | 345,052 | — |
| — | Director | 328,743 | — |
| — | Chief Financial Officer | 309,092 | — |
| — | Director | 240,220 | — |
| — | Chief Medical Officer | 213,387 | — |
| — | Chief People Officer | 210,450 | — |
| — | Director | 206,212 | — |
| — | Chief Technology Officer | 177,171 | — |
| — | Chief Sales Officer | 147,948 | — |
| — | Director | 96,992 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SOPH quote page; the site-wide leaderboard is on the insider transactions hub.